NZ587504A - Benzopyrazole derivatives as ERK inhibitors - Google Patents

Benzopyrazole derivatives as ERK inhibitors

Info

Publication number
NZ587504A
NZ587504A NZ587504A NZ58750409A NZ587504A NZ 587504 A NZ587504 A NZ 587504A NZ 587504 A NZ587504 A NZ 587504A NZ 58750409 A NZ58750409 A NZ 58750409A NZ 587504 A NZ587504 A NZ 587504A
Authority
NZ
New Zealand
Prior art keywords
cancer
cancers
carcinoma
erk inhibitors
thyroid
Prior art date
Application number
NZ587504A
Other languages
English (en)
Inventor
Alan B Cooper
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ587504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NZ587504A publication Critical patent/NZ587504A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ587504A 2008-02-21 2009-02-19 Benzopyrazole derivatives as ERK inhibitors NZ587504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (1)

Publication Number Publication Date
NZ587504A true NZ587504A (en) 2012-09-28

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ587504A NZ587504A (en) 2008-02-21 2009-02-19 Benzopyrazole derivatives as ERK inhibitors

Country Status (23)

Country Link
US (1) US8716483B2 (OSRAM)
EP (1) EP2260031B1 (OSRAM)
JP (1) JP5276676B2 (OSRAM)
KR (1) KR20100117123A (OSRAM)
CN (1) CN102015693B (OSRAM)
AR (1) AR070460A1 (OSRAM)
AU (1) AU2009215534B8 (OSRAM)
BR (1) BRPI0908120A8 (OSRAM)
CA (1) CA2714479A1 (OSRAM)
CL (1) CL2009000394A1 (OSRAM)
CO (1) CO6300939A2 (OSRAM)
EC (1) ECSP10010415A (OSRAM)
ES (1) ES2556353T3 (OSRAM)
IL (1) IL207530A (OSRAM)
MX (1) MX2010009268A (OSRAM)
MY (1) MY152271A (OSRAM)
NZ (1) NZ587504A (OSRAM)
PE (1) PE20091491A1 (OSRAM)
RU (1) RU2525389C2 (OSRAM)
SG (1) SG188179A1 (OSRAM)
TW (1) TWI398441B (OSRAM)
WO (1) WO2009105500A1 (OSRAM)
ZA (2) ZA201005909B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
EP2448942B1 (en) 2009-07-02 2014-09-24 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
CN103270029B (zh) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
AU2011329067A1 (en) * 2010-11-16 2013-05-30 Medimmune, Llc Regimens for treatments using anti-IGF antibodies
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
UA116774C2 (uk) 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
ES2716008T3 (es) * 2012-07-18 2019-06-07 Sunshine Lake Pharma Co Ltd Derivados heterocíclicos nitrogenados y su aplicación en fármacos
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX2015004041A (es) * 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
WO2014140073A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
US9624228B2 (en) 2013-10-03 2017-04-18 Kura Oncology, Inc. Inhibitors of ERK and methods of use
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
RU2017125322A (ru) 2014-12-18 2019-01-18 Мерк Шарп И Доум Корп. (s)-n-(3-(6-изопропоксипиридин-3-ил)-1h-индазол-5-ил)-1-(2-(4-(4-(1-метил-1h-1,2,4-триазол-3-ил)фенил)-3,6-дигидропиридин-1(2н)-ил)-2-оксоэтил)-3-(метилтио)пирролидин-3-карбоксамидные композиции для фармацевтических препаратов
WO2016100152A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
CN107849053B (zh) 2015-04-03 2020-10-30 里科瑞尔姆Ip控股有限责任公司 螺环化合物
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
CN114867529B (zh) 2019-10-09 2024-09-27 拜耳公司 作为农药的新的杂芳基三唑化合物
TWI765451B (zh) 2019-12-06 2022-05-21 大陸商南京明德新藥研發有限公司 作為erk抑制劑的螺環類化合物及其應用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU3215197A (en) 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1207864A2 (en) 2000-02-05 2002-05-29 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
WO2001057022A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
HK1052934B (en) 2000-09-15 2007-01-12 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
WO2002022604A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2429258A1 (en) 2000-11-20 2002-06-13 Scios Inc. Piperidine/piperazine-type inhibitors of p38 kinase
CA2432131C (en) 2000-12-21 2008-07-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CN1300116C (zh) 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
EP1461334A2 (en) 2001-04-27 2004-09-29 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
JP4357295B2 (ja) 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用
ATE491701T1 (de) 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
EP1438295B1 (en) 2001-10-23 2012-08-15 Merck Serono SA Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
ATE450530T1 (de) 2003-03-13 2009-12-15 Vertex Pharma Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2004293035A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
WO2005063258A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
JP2007532615A (ja) 2004-04-13 2007-11-15 アステックス、セラピューティックス、リミテッド 医薬化合物
US7358258B2 (en) 2004-05-14 2008-04-15 Vertex Pharmaceuticals Incorporated Prodrugs of an ERK protein kinase inhibitor
HUE047130T2 (hu) 2004-05-14 2020-04-28 Vertex Pharma Pirrol-származékok mint az erk-fehérjekinázok inhibitorai és ilyen vegyületeket tartalmazó gyógyászati készítmények
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
WO2006071644A1 (en) 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
RU2442778C9 (ru) 2005-12-13 2012-08-10 Шеринг Корпорейшн Новые соединения, действующие как ингибиторы erk
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
US20090062355A1 (en) 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
EP2548558A1 (en) 2007-03-28 2013-01-23 Pharmacyclics, Inc. Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase
TW200911262A (en) * 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
RU2487873C2 (ru) 2007-06-08 2013-07-20 Эбботт Лэборетриз 5-замещенные индазолы в качестве ингибиторов киназы
WO2008156739A1 (en) 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors

Also Published As

Publication number Publication date
JP5276676B2 (ja) 2013-08-28
US20110189192A1 (en) 2011-08-04
PE20091491A1 (es) 2009-09-25
CA2714479A1 (en) 2009-08-27
RU2010138635A (ru) 2012-03-27
CL2009000394A1 (es) 2011-02-11
EP2260031B1 (en) 2015-10-07
US8716483B2 (en) 2014-05-06
JP2011513225A (ja) 2011-04-28
ES2556353T3 (es) 2016-01-15
AU2009215534B8 (en) 2014-07-10
AU2009215534A2 (en) 2010-12-23
ECSP10010415A (es) 2010-09-30
BRPI0908120A2 (OSRAM) 2017-08-22
ZA201005909B (en) 2014-03-26
MY152271A (en) 2014-09-15
AU2009215534A8 (en) 2014-07-10
CN102015693B (zh) 2014-10-29
IL207530A0 (en) 2010-12-30
SG188179A1 (en) 2013-03-28
MX2010009268A (es) 2010-09-14
CO6300939A2 (es) 2011-07-21
TWI398441B (zh) 2013-06-11
TW200948799A (en) 2009-12-01
IL207530A (en) 2014-08-31
WO2009105500A1 (en) 2009-08-27
AU2009215534A1 (en) 2009-08-27
KR20100117123A (ko) 2010-11-02
ZA201400396B (en) 2014-12-23
RU2525389C2 (ru) 2014-08-10
AR070460A1 (es) 2010-04-07
ES2556353T8 (es) 2017-10-13
EP2260031A1 (en) 2010-12-15
CN102015693A (zh) 2011-04-13
BRPI0908120A8 (pt) 2017-10-24
AU2009215534B2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
NZ587504A (en) Benzopyrazole derivatives as ERK inhibitors
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
NZ594383A (en) Aminopyrimidines useful as kinase inhibitors
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
NZ576425A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
PH12017502334A1 (en) Polycyclic amide derivative as cdk9 inhibitors
MX369989B (es) Inhibidores de serina/treonina cinasa para el tratamiento de enfermedades hiperproliferativas.
PH12018502572A1 (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
TW200618800A (en) Heterocyclic compounds
NZ561609A (en) 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
NZ602350A (en) Kinase inhibitors and method of treating cancer with same
JP2010501572A5 (OSRAM)
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
HK1246645A1 (zh) 细胞周期蛋白依赖性激酶的抑制剂
GEAP202115385A (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
NZ607337A (en) Antibodies for epidermal growth factor receptor 3 (her3)
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
WO2007092646A3 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Legal Events

Date Code Title Description
S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO INVENTOR (72)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 FEB 2016 BY AJ PARK

Effective date: 20130429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2017 BY THOMSON REUTERS

Effective date: 20160115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2018 BY THOMSON REUTERS

Effective date: 20170120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2019 BY THOMSON REUTERS

Effective date: 20180112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2020 BY THOMSON REUTERS

Effective date: 20190119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2021 BY THOMSON REUTERS

Effective date: 20200116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2022 BY THOMSON REUTERS

Effective date: 20210112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2023 BY THOMSON REUTERS

Effective date: 20211231

LAPS Patent lapsed